Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from HC Wainwright

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 286.10% from the company’s previous close. Several […]